相关实验视频

Updated: Jan 18, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

将"冷"转换为"热"的肝细胞癌,以改善免疫疗法 (评论)

Ching-Hua Hsieh¹, Pei-Chin Chuang²

¹Department of Plastic Surgery, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 83301, Taiwan, R.O.C.

Molecular medicine reports

|January 16, 2026

概括

肝细胞癌 (HCC) 瘤通常是肝细胞癌 (HCC) 瘤.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
癌症研究癌症研究

背景情况:

肝细胞癌 (HCC) 通常呈现出一种免疫学上"冷"的瘤微环境 (TME).
这种"冷"的TME的特点是有限的T细胞透和强大的免疫抑制机制.
这些因素显著阻碍了免疫检查点抑制剂 (ICI) 等免疫疗法的有效性.

研究的目的:

审查HCC的免疫格局及其冷TME背后的机制.
描述当前用于将HCC TME从"冷"转换为"热" (免疫反应) 的战略.
讨论免疫细胞,细胞因子和瘤途径在免疫排除和耐受性中的作用.

主要方法:

审查关于HCC免疫学和免疫治疗的现有文献.
对驱动HCC免疫排斥和耐受性的机制的分析.
讨论用于重新编程HCC TME的治疗策略.

主要成果:

目前正在探索各种策略,以提高HCC的免疫疗法疗效.
组合疗法 (例如,用抗血管原剂或局部区域疗法进行的ICI) 是有前途的.
针对免疫抑制细胞,瘤病毒,疫苗,细胞疗法和表观遗传调节器是活跃的研究领域.

结论:

从冷到热重新编程HCC TME是改善免疫治疗反应的关键策略.
临床证据表明,结合疗法改善了结局.
需要进一步的研究来优化治疗方法,确定生物标志物,并发现可持续的患者益处的新目标.

关键词:

透T细胞的透情况肝细胞癌是肝细胞癌.免疫检查点抑制剂免疫检查点抑制剂免疫疗法免疫疗法瘤微环境是一个微环境.

更多相关视频

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma

Published on: April 25, 2025

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.